View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, March 8 (HealthDay News) -- A two-point improvement on the Brief Pain Inventory (BPI) represents the minimum clinically important difference (MCID) for patients with fibromyalgia pain, corresponding to a 30 to 35 percent improvement from baseline, according to a study published online Feb. 10 in Arthritis Care & Research.
Philip J. Mease, M.D., of the University of Washington School of Medicine in Seattle, and colleagues used data from four studies evaluating duloxetine as a treatment for fibromyalgia. They estimated the MCID for the BPI average pain item score and the BPI severity score by anchoring them against the Patient Global Impression of Improvement scale.
The researchers determined that an approximately two-point improvement on both the BPI average pain item and severity scores represented the MCID. These MCIDs corresponded to a 30 to 35 percent improvement in baseline pain in both scores.
"These findings may be beneficial for use in designing clinical trials in which the BPI is used to evaluate improvements in pain severity," the authors write.
The study received financial support from Eli Lilly and Company and Boehringer Ingelheim GmbH.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top